2018年10月28日 · Using the RDG platform, we developed a hybrid, multimodal nanotherapeutic system that incorporates the anti-NF-κB agent, p65-shRNA, for the effective treatment of …

A knock down of endogenous Grx-1 by siRNA or pretreatment with an inhibitor of Grx-1 activity, CdCl(2), abolishes p65-SSG formation. In addition, Grx-1 siRNA blocks the inhibition of p65 …

2017年10月9日 · Here we demonstrated that p65 can bind to HSC70 with four consensus recognition motif in its RHD domain and be constitutively transported to the lysosome …

2018年10月28日 · This multimodal therapeutic system was prepared by complexing RDG nanovectors with p65-shRNA, an anti-NF-κB agent, via the electrostatic interactions between …

Because 15-deoxy-Δ12,14-prostaglandin J 2 (15 d-PGJ 2) is an electrophilic prostaglandin that can increase glutathione (GSH) levels and augment reactive oxygen species (ROS) …

2024年3月13日 · Using a microglial culture supernatant (MCS) transfer model, we found that inhibiting LRRK2 or downregulating ferroptosis in BV2 cells prevented SH-SY5Y cell …

Download scientific diagram | RNAi modulation of Nrf2, Keap1 and p65 influences the level of GSH. Cells were transfected for 48h with RNAi and treated for 6h with DNCB. Keap1 depletion...

通过从NIR激光照射和高细胞内GSH浓度双重刺激，可实现复合物中shRNA的胞质释放，从而有效地抑制转移性4T1乳腺癌细胞的基因沉默，从而抑制细胞增殖和侵袭。 更重要的是，由于EPR …

2018年10月28日 · This multimodal therapeutic system was prepared by complexing RDGs with shRNA through electrostatic interactions between cationic DSPEI and negatively charged p65 …

We explored the underlying mechanism of Glrx in the pathogenesis of LAM. Our data suggested that Rapamycin‐independently hyperactivation of Glrx in LAM attenuated intracellular oxidative …